Kojima J, Nakamura N, Kanatani M, Akiyama M
Cancer Res. 1982 Jul;42(7):2857-60.
The changes in glycosaminoglycans in livers of rats with 3'-methyl-4-dimethylaminoazobenzene-induced hepatic cancer were examined and compared with those in fetal liver. The incorporation of 35S into sulfated glycosaminoglycans in hepatic cancer tissue was also studied after i.p. injection of Na(2)35SO4. The major component of glycosaminoglycans in healthy adult rat liver was heparan sulfate (61.7%), with hyaluronic acid (21.1%), dermatan sulfate (13.1%), and chondroitin sulfate (4.0%) as minor components. The quantities of all of the examined glycosaminoglycans were higher in tumors than in normal liver, but chondroitin sulfate and hyaluronic acid were more prevalent in the tumors (about 51 and 7 times higher, respectively). As a result, the share of heparan sulfate was decreased (37.1%) in the tumors. The high content of chondroitin sulfate (about 30 times) and the decreased share of heparan sulfate (29.0%) were also observed in fetal liver. The incorporation of 35S into individual glycosaminoglycans varied markedly. Approximately 90% of the label in glycosaminoglycans of healthy liver was found in a heparan sulfate fraction 4 hr after injection. In hepatic cancer tissue, however, 35S incorporation into both chondroitin sulfate and dermatan sulfate fractions was increased about 6.5- and 5.6-fold, respectively, of those in healthy liver.
研究了3'-甲基-4-二甲基氨基偶氮苯诱导的肝癌大鼠肝脏中糖胺聚糖的变化，并与胎儿肝脏中的变化进行了比较。腹腔注射Na₂³⁵SO₄后，还研究了³⁵S在肝癌组织中硫酸化糖胺聚糖的掺入情况。健康成年大鼠肝脏中糖胺聚糖的主要成分是硫酸乙酰肝素（61.7%），次要成分是透明质酸（21.1%）、硫酸皮肤素（13.1%）和硫酸软骨素（4.0%）。所有检测的糖胺聚糖在肿瘤中的含量均高于正常肝脏，但硫酸软骨素和透明质酸在肿瘤中更为普遍（分别约高51倍和7倍）。结果，肿瘤中硫酸乙酰肝素的比例下降（37.1%）。在胎儿肝脏中也观察到硫酸软骨素含量高（约30倍）和硫酸乙酰肝素比例下降（29.0%）。³⁵S掺入各个糖胺聚糖的情况有显著差异。注射后4小时，健康肝脏糖胺聚糖中约90%的标记物存在于硫酸乙酰肝素部分。然而，在肝癌组织中，³⁵S掺入硫酸软骨素和硫酸皮肤素部分的量分别比健康肝脏增加了约6.5倍和5.6倍。
